| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 6253 | 2005 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4447 | 2013 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2283 | 2015 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 2248 | 2012 |
| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition … S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ... Journal of clinical oncology 31 (7), 860-867, 2013 | 1792 | 2013 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Journal of Clinical Oncology 35 (32), 3638-3646, 2017 | 1550 | 2017 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1266 | 2017 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 994 | 2018 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 963 | 2018 |
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ... Journal of Clinical Oncology 28 (30), 4594-4600, 2010 | 780 | 2010 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 660 | 2018 |
| Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer A Di Leo, HL Gomez, Z Aziz, Z Zvirbule, J Bines, MC Arbushites, ... Journal of Clinical Oncology 26 (34), 5544-5552, 2008 | 561 | 2008 |
| Dissecting the heterogeneity of triple-negative breast cancer O Metzger-Filho, A Tutt, E De Azambuja, KS Saini, G Viale, S Loi, ... Journal of clinical oncology 30 (15), 1879-1887, 2012 | 513 | 2012 |
| MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer S Johnston, M Martin, A Di Leo, SA Im, A Awada, T Forrester, M Frenzel, ... NPJ breast cancer 5 (1), 5, 2019 | 506 | 2019 |
| Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples M Tanner, D Gancberg, A Di Leo, D Larsimont, G Rouas, MJ Piccart, ... The American journal of pathology 157 (5), 1467-1472, 2000 | 502 | 2000 |
| Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled … V Galimberti, BF Cole, G Viale, P Veronesi, E Vicini, M Intra, G Mazzarol, ... The Lancet Oncology 19 (10), 1385-1393, 2018 | 490* | 2018 |
| Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial S Loi, A Giobbie-Hurder, A Gombos, T Bachelot, R Hui, G Curigliano, ... The Lancet Oncology 20 (3), 371-382, 2019 | 432* | 2019 |
| 1st International consensus guidelines for advanced breast cancer (ABC 1) F Cardoso, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, ... The Breast 21 (3), 242-252, 2012 | 420 | 2012 |
| Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement S Guiu, S Michiels, F André, J Cortes, C Denkert, A Di Leo, BT Hennessy, ... Annals of oncology 23 (12), 2997-3006, 2012 | 409 | 2012 |
| Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites D Gancberg, A Di Leo, F Cardoso, G Rouas, M Pedrocchi, M Paesmans, ... Annals of Oncology 13 (7), 1036-1043, 2002 | 402 | 2002 |
Christos SotiriouUniversité Libre de Bruxelles在 bordet.be 的电子邮件经过验证
